Latest News

A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.

The FDA designates zoldonrasib as a breakthrough therapy for KRAS G12D-mutated lung cancer, highlighting its promising efficacy and safety profile.

The FDA clears KLN-1010, a groundbreaking in vivo gene therapy for relapsed multiple myeloma, enhancing CAR-T treatment accessibility and efficacy.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

CPI-008 receives orphan drug designation, enhancing surgical imaging for pancreatic cancer and promising improved outcomes in challenging surgeries.

Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies.

A new trial explores the effectiveness of calderasib combined with pembrolizumab for advanced lung cancer patients with the KRAS G12C mutation.

During a live event, Jan Drappatz, MD, and participants discussed which patients with glioma should receive IDH inhibitors and what next steps could identify who will benefit.

A recent study reveals CAR T-cell therapy patients in Europe experience quality of life comparable to the general population, yet face ongoing physical and mental challenges.

A recent analysis highlights the efficacy of melphalan/HDS for metastatic uveal melanoma, showing improved outcomes in patients with lower hepatic tumor burden.

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed their approaches to TKI dose modification and immune checkpoint inhibitor rechallenge in advanced renal cell carcinoma.

A new drug application for rusfertide aims to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient outcomes.

A phase 2 study reveals that combining brentuximab vedotin with gemcitabine shows promising efficacy and safety for relapsed peripheral T-cell lymphoma patients.

Sevabertinib receives breakthrough therapy designation for treating advanced HER2-mutant non-small cell lung cancer, promising new hope for patients.

Denileukin diftitox transforms CTCL treatment by targeting malignant T cells, offering hope for patients with limited options and severe symptoms.

A novel antibody combination shows promising results in treating recurrent ovarian cancer, offering hope for better immunotherapy options.

New genomic insights reveal how pirtobrutinib effectively targets resistance in relapsed CLL, reshaping treatment strategies for better outcomes.

New research reveals that combining midostaurin with standard chemotherapy significantly improves survival rates and reduces minimal residual disease in AML patients.

Patients with Waldenström macroglobulinemia experience comparable outcomes when switching from ibrutinib to zanubrutinib, with improved safety profiles.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

Research uncovers distinct sex-based differences in exosomal ncRNA dysregulation in multiple myeloma, highlighting the need for personalized treatment strategies.

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent high-grade bladder cancer, emphasizing patient-centered care.

Heather Cooper Ortner leads the International Myeloma Foundation, focusing on advancing research, improving patient access, and enhancing support for myeloma care.

Dena Champion leads a transformative initiative for cancer survivors, blending nutrition, community, and gardening to promote health and well-being.

Key FDA action dates in early 2026 promise to transform treatment options for solid tumors and rare hematologic malignancies, enhancing patient care.

Digital pathology revolutionizes diagnostics with AI and imaging, enhancing accuracy, speed, and personalized medicine for improved patient care.

Discover groundbreaking advancements in glioblastoma treatment, including FDA approvals and innovative therapies reshaping neuro-oncology in 2025.

Explore groundbreaking FDA approvals in oncology for 2025, enhancing treatment options for breast cancer, lung cancer, and rare tumors.